Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:United_States_federal_law
|
| gptkbp:affects |
pharmaceutical industry
brand-name drug manufacturers generic drug manufacturers |
| gptkbp:codifiedIn |
gptkb:21_U.S.C._§_355
gptkb:35_U.S.C._§_156 |
| gptkbp:dateEnacted |
1984-09-24
|
| gptkbp:enactedBy |
gptkb:United_States_Congress
|
| https://www.w3.org/2000/01/rdf-schema#label |
Hatch-Waxman Act
|
| gptkbp:namedAfter |
gptkb:Henry_Waxman
gptkb:Orrin_Hatch |
| gptkbp:nickname |
gptkb:Hatch-Waxman_Amendments
|
| gptkbp:officialName |
gptkb:Drug_Price_Competition_and_Patent_Term_Restoration_Act
|
| gptkbp:provides |
gptkb:Abbreviated_New_Drug_Application
market exclusivity for generics patent term extension |
| gptkbp:purpose |
balance pharmaceutical innovation and competition
facilitate generic drug entry |
| gptkbp:relatedTo |
gptkb:Food_and_Drug_Administration
gptkb:United_States_patent_law |
| gptkbp:signedBy |
gptkb:Ronald_Reagan
|
| gptkbp:bfsParent |
gptkb:Abbreviated_New_Drug_Applications
gptkb:Henry_Waxman |
| gptkbp:bfsLayer |
6
|